Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Imagion Biosystems Ltd. ( (AU:IBX) ) is now available.
Imagion Biosystems has announced positive results from its collaboration with Wayne State University on the MagSense® HER2 Imaging Agent, which is a significant step towards their Phase 2 clinical trial for HER2 breast cancer. The study indicates that a lower dose of the imaging agent is detectable, potentially improving patient safety and care experience. Additionally, optimized imaging protocols and the integration of AI-ready imaging data suggest advancements in diagnostic precision. The company remains on track to submit its Investigational New Drug application to the FDA by the end of 2025, with the Phase 2 study expected to commence in early 2026, pending regulatory approval.
More about Imagion Biosystems Ltd.
Imagion Biosystems (ASX: IBX) is a clinical-stage medical imaging company focused on transforming cancer diagnosis and treatment. The company is developing MagSense®, a pioneering MRI imaging agent that allows for earlier and more precise cancer detection. Their technology utilizes non-radioactive, bio-safe magnetic nanoparticles to enhance diagnostic accuracy across various cancers, including HER2+ breast cancer, prostate, and ovarian cancers.
Average Trading Volume: 8,485,247
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$11.24M
See more data about IBX stock on TipRanks’ Stock Analysis page.